SpringWorks Therapeutics, Inc.
SWTXDelisted Jul 1, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001773427
SpringWorks Therapeutics, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 2, 2025; 223 institutions reported holding it in 13F filings for Q2 2025, worth $3.65B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:15 PM ET
Revenue flow, FY2024
Where the revenue went in FY2024, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2024: $258.1M (134.7% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2025 | Feb 27, 2024 | Feb 28, 2023 | Feb 24, 2022 | Feb 25, 2021 |
| Revenue | $191.6M | $5.45M | $0 | $0 | $35.0M |
| Cost of revenue | $12.6M | $422.0K | – | – | – |
| Operating expenses | – | – | $280.7M | $173.5M | $81.3M |
| Research and development | $200.5M | $150.5M | $146.1M | $101.7M | $51.9M |
| Selling, general and administrative | $256.7M | $197.6M | $134.6M | $71.8M | $29.5M |
| Operating income | -$278.1M | -$343.0M | -$280.7M | -$173.5M | -$46.3M |
| Net income | -$258.1M | -$325.1M | -$277.4M | -$173.9M | -$45.6M |
| EPS, basic | $-3.48 | $-5.15 | $-5.21 | – | – |
| EPS, diluted | $-3.48 | $-5.15 | $-5.21 | – | – |
| Weighted shares, basic | 74.1M | 63.1M | 53.3M | 48.5M | – |
| Weighted shares, diluted | 74.1M | 63.1M | 53.3M | 48.5M | – |
| Margins and growth | |||||
| Operating margin | -145.2% | -6297.3% | – | – | -132.4% |
| Net margin | -134.7% | -5968.5% | – | – | -130.2% |
| Revenue growth, year over year | +3,417.3% | – | – | −100.0% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2025 | Feb 27, 2024 | Feb 28, 2023 | Feb 24, 2022 | Feb 25, 2021 |
| Cash and equivalents | $69.8M | $176.1M | $67.5M | $104.0M | $147.1M |
| Short-term investments | – | – | $524.7M | $269.5M | $361.4M |
| Accounts receivable | $46.2M | $5.93M | – | – | – |
| Inventory | $10.2M | $3.10M | – | – | – |
| Total current assets | $380.5M | $500.9M | $599.8M | $382.9M | $513.4M |
| Property, plant and equipment | $19.7M | $17.9M | $13.6M | $3.19M | $1.07M |
| Intangible assets | $15.6M | $11.2M | – | – | – |
| Total assets | $587.3M | $725.8M | $630.2M | $452.5M | $576.2M |
| Accounts payable | $12.2M | $7.40M | $8.01M | $3.43M | $1.35M |
| Total current liabilities | $100.0M | $78.2M | $51.0M | $30.0M | $17.6M |
| Total liabilities | $106.2M | $99.6M | $72.0M | $30.1M | $19.1M |
| Shareholders' equity | $481.1M | $626.2M | $558.2M | $422.4M | $557.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2025 | Feb 27, 2024 | Feb 28, 2023 | Feb 24, 2022 | Feb 25, 2021 |
| Operating cash flow | -$175.6M | -$222.8M | -$161.6M | -$127.9M | -$32.2M |
| Capital expenditures | $4.45M | $7.38M | $10.2M | $2.02M | $642.0K |
| Free cash flow | -$180.1M | -$230.2M | -$171.8M | -$129.9M | -$32.8M |
| Depreciation and amortization | $3.47M | $1.67M | – | – | – |
| Stock-based compensation | $109.1M | $94.5M | $73.0M | $38.4M | $10.0M |
| Share buybacks | $8.44M | $2.80M | $1.34M | – | – |
| Investing cash flow | $64.5M | $34.8M | -$215.6M | $83.6M | -$418.8M |
| Financing cash flow | $4.76M | $296.6M | $340.7M | $1.16M | $270.5M |
| Net change in cash | -$106.3M | $108.6M | -$36.5M | -$43.1M | – |
| Ratio | |||||
| Stock-based compensation, % of revenue | 57.0% | 1735.5% | – | – | 28.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| May 2, 2025 | 75.3M | +1.7% | SEC |
| Feb 14, 2025 | 74.9M | +1.6% | SEC |
| Nov 5, 2024 | 74.4M | +18.9% | SEC |
| Aug 1, 2024 | 74.3M | +18.7% | SEC |
| Apr 26, 2024 | 74.1M | +18.5% | SEC |
| Feb 21, 2024 | 73.8M | +18.1% | SEC |
| Oct 30, 2023 | 62.6M | +0.3% | SEC |
| Jul 28, 2023 | 62.6M | +26.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.